GRI Bio, Inc.
- Tom Shelly
Tom Shelly has extensive work experience in various roles in the biotech and clinical research industry. Tom is currently the Global Lead Clinical & Logistics Management at GRI Bio, Inc. Prior to this, they served as the COO/CFO of Attenuate Therapeutics Ltd. Tom held the position of General Manager at Sublimity Therapeutics, where they led the global Phase 2b clinical trial for the treatment of Moderate to Severe Ulcerative Colitis. Before that, they worked at Cambridge Clinical Research as a Consultative Clinical Development Project Manager and also served as the Founder and Managing Director. Additionally, they held the position of Vice President of Finance and Operations at Tecan.
Tom Shelly obtained a Master of Business Administration (MBA) degree in Business Administration and Management, General from UNC Kenan-Flagler Business School between 1993 and 1995. Tom also holds the certification of Fellow of The Institute of Chartered Accountants in Ireland, which they obtained in 1983.
Org chart
This person is not in the org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
